Ipilimumab-induced immune-related renal failure--a case report.
Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA. pforde1@jhmi.edu
Patrick M
PM
Forde
Kathy
K
Rock
Graham
G
Wilson
Kenneth J
KJ
O'Byrne
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000074324:Ipilimumab; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011859:Radiography; D012878:Skin Neoplasms / Q000188:drug therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D000074324:Ipilimumab; D003404:Creatinine; D008775:Methylprednisolone